Axel C Carlsson1, Per Wändell2, Danijela Gasevic3, Jan Sundquist4, Kristina Sundquist4. 1. Division of Family Medicine, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Huddinge, Sweden; Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. Electronic address: axelcefam@hotmail.com. 2. Division of Family Medicine, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Huddinge, Sweden. 3. Centre for Population Health Sciences, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK. 4. Center for Primary Health Care Research, Lund University, Malmö, Sweden; Stanford Prevention Research Center, Stanford University School of Medicine, Palo Alto, CA, USA.
Abstract
BACKGROUND: We aimed to study differences in the prescribing of warfarin, aspirin and statins to patients with atrial fibrillation (AF) in socio-economically diverse neighborhoods. We also aimed to explore the effects of neighborhood deprivation on the relationship between CHADS2 risk score and warfarin prescription. METHODS: Data were obtained from primary health care records that contained individual clinical data that were linked to national data on neighborhood of residence and a deprivation index for different neighborhoods. Logistic regression was used to estimate the potential neighborhood differences in prescribed warfarin, aspirin and statins, and the association between the CHADS2 score and prescribed warfarin treatment, in neighborhoods with high, middle (referent) and low socio-economic (SES). RESULTS: After adjustment for age, socio-economic factors, co-morbidities and moves to neighborhoods with different SES during follow-up, adults with AF living in high SES neighborhoods were more often prescribed warfarin (men odds ratio (OR) (95% confidence interval (CI): 1.44 (1.27-1.62); and women OR (95% CI): 1.19 (1.05-1.36)) and statins (men OR (95% CI): 1.23 (1.07-1.41); women OR (95% CI): 1.23 (1.05-1.44)) compared to their counterparts residing in middle SES. Prescription of aspirin was lower in men from high SES neighborhoods (OR (95% CI): 0.75 (0.65-0.86)) than in those from middle SES neighborhoods. Higher CHADS2 risk scores were associated with higher warfarin prescription which remained after adjustment for neighborhood SES. CONCLUSIONS: The apparent inequalities in pharmacotherapy seen in the present study call for resource allocation to primary care in neighborhoods with low and middle socio-economic status.
BACKGROUND: We aimed to study differences in the prescribing of warfarin, aspirin and statins to patients with atrial fibrillation (AF) in socio-economically diverse neighborhoods. We also aimed to explore the effects of neighborhood deprivation on the relationship between CHADS2 risk score and warfarin prescription. METHODS: Data were obtained from primary health care records that contained individual clinical data that were linked to national data on neighborhood of residence and a deprivation index for different neighborhoods. Logistic regression was used to estimate the potential neighborhood differences in prescribed warfarin, aspirin and statins, and the association between the CHADS2 score and prescribed warfarin treatment, in neighborhoods with high, middle (referent) and low socio-economic (SES). RESULTS: After adjustment for age, socio-economic factors, co-morbidities and moves to neighborhoods with different SES during follow-up, adults with AF living in high SES neighborhoods were more often prescribed warfarin (men odds ratio (OR) (95% confidence interval (CI): 1.44 (1.27-1.62); and women OR (95% CI): 1.19 (1.05-1.36)) and statins (men OR (95% CI): 1.23 (1.07-1.41); women OR (95% CI): 1.23 (1.05-1.44)) compared to their counterparts residing in middle SES. Prescription of aspirin was lower in men from high SES neighborhoods (OR (95% CI): 0.75 (0.65-0.86)) than in those from middle SES neighborhoods. Higher CHADS2 risk scores were associated with higher warfarin prescription which remained after adjustment for neighborhood SES. CONCLUSIONS: The apparent inequalities in pharmacotherapy seen in the present study call for resource allocation to primary care in neighborhoods with low and middle socio-economic status.
Authors: Per E Wändell; Axel C Carlsson; Kristina Sundquist; Sven-Erik Johansson; Jan Sundquist Journal: Int J Cardiol Date: 2011-08-17 Impact factor: 4.164
Authors: A S Go; E M Hylek; K A Phillips; L H Borowsky; L E Henault; Y Chang; J V Selby; D E Singer Journal: Circulation Date: 2000-07-04 Impact factor: 29.690
Authors: Karin M Henriksson; Bahman Farahmand; Saga Johansson; Signild Asberg; Andreas Terént; Nils Edvardsson Journal: Int J Cardiol Date: 2009-01-13 Impact factor: 4.164
Authors: Justin M Bachmann; Maulik Majmudar; Christine Tompkins; Roger S Blumenthal; Joseph E Marine Journal: Cardiol Rev Date: 2008 Jul-Aug Impact factor: 2.644
Authors: Axel C Carlsson; Per Wändell; Kristina Sundquist; Sven-Erik Johansson; Jan Sundquist Journal: Hypertens Res Date: 2014-03-06 Impact factor: 3.872
Authors: Per Wändell; Axel C Carlsson; Danijela Gasevic; Lars Wahlström; Jan Sundquist; Kristina Sundquist Journal: Ann Med Date: 2016-01-13 Impact factor: 4.709
Authors: Per Wändell; Axel C Carlsson; Danijela Gasevic; Jan Sundquist; Kristina Sundquist Journal: Int J Cardiol Date: 2015-09-21 Impact factor: 4.164
Authors: Axel C Carlsson; Xinjun Li; Martin J Holzmann; Per Wändell; Danijela Gasevic; Jan Sundquist; Kristina Sundquist Journal: Heart Date: 2016-02-10 Impact factor: 5.994
Authors: Axel C Carlsson; Xinjun Li; Martin J Holzmann; Johan Ärnlöv; Per Wändell; Danijela Gasevic; Jan Sundquist; Kristina Sundquist Journal: Int J Stroke Date: 2017-04-07 Impact factor: 5.266
Authors: Annie McDermott; Nadejda Kim; Leslie R M Hausmann; Jared W Magnani; Chester B Good; Terrence M A Litam; Maria K Mor; Toluwa D Omole; Walid F Gellad; Michael J Fine; Utibe R Essien Journal: J Gen Intern Med Date: 2022-09-23 Impact factor: 6.473
Authors: Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Sven-Erik Johansson; Jan Sundquist; Kristina Sundquist Journal: Scand Cardiovasc J Date: 2016-08-18 Impact factor: 1.589
Authors: Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Sven-Erik Johansson; Jan Sundquist; Kristina Sundquist Journal: Int J Cardiol Date: 2016-07-09 Impact factor: 4.164
Authors: Per Wändell; Axel C Carlsson; Danijela Gasevic; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist Journal: Eur J Public Health Date: 2018-12-01 Impact factor: 3.367
Authors: Utibe R Essien; Jelena Kornej; Amber E Johnson; Lucy B Schulson; Emelia J Benjamin; Jared W Magnani Journal: Nat Rev Cardiol Date: 2021-06-02 Impact factor: 32.419
Authors: Utibe R Essien; Megan E McCabe; Kiarri N Kershaw; Quentin R Youmans; Michael J Fine; Clyde W Yancy; Sadiya S Khan Journal: J Gen Intern Med Date: 2021-07-08 Impact factor: 6.473